The ‘super powerful' tool behind a pharmaceutical giant's global regulatory operation
Rahman Ahrar is a project management office director with a challenge on his hands. His role at the pharmaceutical company GSK is to run the project management office for initiatives that improve the delivery of regulatory applications for new treatments. This means facing the challenge of coordinating multiple innovation projects at once.
Keeping track of all these projects and ensuring that teams can post updates on their progress, share data and keep managers apprised of developments is a key task for Ahrar.
His office has deployed a variety of workflow software to help coordinate this wide range of projects, and cloud-based Smartsheet software has played a significant role in seamlessly managing many initiatives.
'Smartsheet has been instrumental in the past few years for my various teams thanks to its robust and flexible capabilities,' says Ahrar.
The software has helped GSK's processes by introducing greater efficiency, transparency and accountability. 'As a result, we have experienced improved coordination among teams, reduced administrative burdens, and enhanced overall project performance,' he says.
Smartsheet's project management toolkit offers comprehensive dashboards, real-time updates and automated workflows, and these 'significantly enhance our ability to deliver projects', says Ahrar.
This is important work. Improving the delivery of regulatory data is an area of significant research for pharmaceutical companies as they strive to bring new medical treatments to market.
'Regulatory operations are a backbone of pharmaceutical companies,' says Ahrar. 'As PMO director, my role is to create a project management office that will manage all these types of regulatory innovation projects,' he says.
Ahrar finds that Smartsheet's wide range of functions makes it an adaptable and scalable solution for his innovation teams as they look for improved ways to present regulatory data.
Particularly impressive are the system's premium applications such as Dynamic View, which allows users to share information with others while maintaining confidentiality. Another key app is Control Center, a project and portfolio management tool that helps users to create consistent projects.
Meanwhile, the premium Smartsheet app data Shuttle allows data to be exported to other databases such as the customer relationship marketing system or the enterprise resource planning (ERP) database. 'If you look at Smartsheet's whole range of capabilities, these make it super powerful compared with competitors,' he says. 'And from a user's perspective, it is very simple to learn. It's not complicated and is very easy to navigate.'
A good example of Smartsheet's versatility was its role in a budget management tool that Ahrar helped build for GSK Consumer, now Haleon. The tool provides the marketing, procurement and finance teams with a way to plan, budget and track expenditure. The tool integrates finance data from the ERP software, which connects the core processes of a business, with Smartsheet to gain a single budget oversight. 'It allows detailed tracking of expenditures, budget allocations and financial forecasts ensuring that we maintain control over our financial resources and support informed decision-making,' says Ahrar.
A powerful feature of Smartsheet is the ability to manage projects with multiple users and external stakeholders, which speeds up communications and builds a single source of truth. For instance, the Smartsheet update request function allows managers to grant temporary access to specific rows and columns for external parties who are not even Smartsheet users. Allowing external parties to update fields helps simplify the process of gathering information while maintaining control over the system.
One project at GSK involved working collaboratively with four external consultancies alongside the internal GSK team. It was a quick turnaround project over 18 weeks that was high profile, high cost and had to be delivered during the pandemic. Smartsheet's ease of use made it simple to convince the four consultancies and the internal team to use the system to work together easily.
Some of the existing digital platforms used by the regulatory operations teams lack certain key features, such as smart notifications, automation or planning. These are essential for smooth working.
Related: Fewer meetings, greater collaboration: how a project management tool helped a crane builder reach new heights
Ahrar has integrated advanced Smartsheet features such as notifications and data visualisations into these platforms. 'These integrations have significantly enhanced our ability to manage tasks and deadlines efficiently, so all team members are informed about critical updates and actions. This has improved coordination, reduced delays, and has created a more streamlined process,' he says.
GSK is developing new treatments in areas such as HIV, oncology and infectious diseases, and improving the delivery of regulatory data is a vital part of getting those treatments to the people who need them.
'Smartsheet has a variety of capabilities for integration, data visualisation and automation and it offers a simple user experience and easy-to-use interface,' says Ahrar. 'Those features make Smartsheet a strong option for us.'
Read more about how Smartsheet empowers customers around the world to make tangible impacts

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 hours ago
- Yahoo
Bharat, GSK to halve price of malaria vaccine by 2028
By Maggie Fick and Jennifer Rigby LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Bharat, GSK to halve price of malaria vaccine by 2028
By Maggie Fick and Jennifer Rigby LONDON (Reuters) -Drugmakers Bharat Biotech and GSK will cut the price of their malaria vaccine to $5 per dose by 2028, more than halving its current cost, they said on Wednesday. The vaccine, Mosquirix or RTS,S, was developed by GSK and the non-profit PATH, and was the first malaria vaccine to get approval from the World Health Organization in 2022. GSK is working on a technology transfer to Bharat, and will continue to supply the adjuvant part of the vaccine to Bharat when the Indian drugmaker fully takes over production of the shot by 2028. A phased reduction in price for the vaccine will begin immediately, GSK said in a statement with Bharat, reaching the target price of $5 by 2028. The price cut was "driven by process improvements, expanded production capacity, cost-effective manufacturing, and minimal profit margins," the statement read. Malaria kills more than 500,000 people annually, mainly children aged five and under in sub-Saharan Africa, according to WHO estimates. Cases and deaths fell significantly between 2000 and 2015, but progress has since stalled and even reversed, with a particular jump in mortality during the COVID-19 pandemic. Many experts have expressed hope that vaccines can help turn the tide in the fight against the mosquito-borne disease. But price has been an issue, particularly when compared to other tools to prevent malaria like bed nets. GSK has previously said it was committed to supplying up to 18 million vaccine doses between 2023 and the end of this year. The company plans to supply 15 million doses annually from 2026-2028, according to a spokesperson. Wednesday's announcement comes as Gavi - a global vaccine group that helps buy childhood vaccines in the world's poorest countries - holds an event in Brussels to raise funding for its work over the next five years, as governments pull back from international aid. GSK and Bharat said the price reduction showed their commitment to Gavi, which has been funding some of the roll-out of the malaria vaccine. Twelve African countries are set to introduce the vaccine in their routine immunisation programmes by the end of this year with Gavi's support. The other approved malaria vaccine, developed by the University of Oxford and the Serum Institute of India, is priced at under $4 a dose. Sign in to access your portfolio


Tom's Guide
21 hours ago
- Tom's Guide
iOS 26 just got a big design upgrade — thanks to your complaints
Apple released iOS 26 Beta 2 this week, adding some new features while also apparently fixing complaints about the new Liquid Glass user interface for iPhone, iPad, and other Apple devices. Liquid Glass refreshed the interface across Apple's different operating systems with a new look and feel that gave it more of a transparent look. However, initial impressions were mixed. We found the look amazing but with some flaws such as app tinting and how Control Center looks. "This feature allowed you to change the color of your app icons — at least in theory. In practice, the finished result made it look like you poured sauce all over your apps," my colleague Josh Render said of the customizable feature. Tom's Guide's John Velasco found that the transparency caused issues with the way Control Center appears. Mostly it appears too busy and can make the settings panel unreadable. "I noticed how the transparency of Liquid Glass clashes with the way the Control Center appears on top of certain elements, like the icons on my home screen, or very busy web pages," he wrote. We were able to find workarounds for both issues, but it requires some finagling with the settings and does reduce the transparency. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. With developer beta 2 for iOS 26, Apple has adjusted the background blur which obscures the home screen more and makes it more readable. Here's an example from X user Aaron Perris, a contributor at Mac Rumors. iOS 26 beta 2 blurs the background of the Control Center 23, 2025 Notifications appears to have received a similar update to make them more readable, though it doesn't look as dramatic as the Control Center change. To be clear, this likely won't be the final look for iOS 26 this is still a developers beta. A public beta won't launch until later this summer followed by the full release ahead of the iPhone 17 launch in the fall. Still, it is clear that Apple appears to be listening to user feedback and adjusting.